DCIT Vs Panacea Biotech Limited (ITAT Delhi)
₹24,000 Exempt Income, ₹3.38 Crore Disallowance: ITAT Rejects Revenue’s Section 14A Arithmetic
A Large Disallowance Against a Small Exempt Receipt
Can an investment-based computation under Rule 8D produce a disallowance of ₹3.38 crore when the exempt income earned during the year is only ₹24,000?
In the case of Panacea Biotech Limited, the Delhi Tribunal answered this question in the assessee’s favour for Assessment Year 2018-19. It upheld deletion of the additional disallowance, observing that the assessee had already voluntarily disallowed an amount equal to its exempt income.
The Tribunal also rejected the Revenue’s attempt to apply the Finance Act, 2022 amendment retrospectively, following the binding decision of the Delhi High Court.
Scrutiny of Investments and Interest Expenditure
The assessee filed its return on 30 November 2018, declaring a loss of ₹113,43,75,129 under the normal provisions and nil book profits.
The return was selected for complete scrutiny through CASS on several issues, including investments, loans, business loss and expenditure relating to exempt income.
During assessment, the Assessing Officer sought details of substantial equity and other investments reflected in the balance sheet. The assessee furnished an investment chart and stated that no new investments had been made during the year.
Want to Read the Complete Judgment?
You have read the free case summary. Unlock the full judgment, the detailed judicial reasoning and the downloadable PDF, along with every other premium judgment on TaxGuru.
Already subscribed? Log in
One subscription covers the entire premium judgment library, not just this case.




